Effects of catecholamines on the AV nodal pacemaker in situ after destroying the SA node.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002395:Catecholamines / Q000494:pharmacology*; D004285:Dogs; D004298:Dopamine / Q000008:administration & dosage / Q000494:pharmacology; D004837:Epinephrine / Q000008:administration & dosage / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D007545:Isoproterenol / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000008:administration & dosage / Q000494:pharmacology; D010138:Pacemaker, Artificial; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012849:Sinoatrial Node / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology; D014628:Vagotomy; D014630:Vagus Nerve / Q000502:physiology
D002395:Catecholamines; D010643:Phenoxybenzamine; D000431:Ethanol; D013779:Tetrodotoxin; D001285:Atropine; D011433:Propranolol; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine